NCT01969292

Brief Summary

Our team has created an automated, real-time software based image analysis tool called Colometer to improve screening colonoscopy providing real time visual feedback on image quality. There are three components to this study. The first is to validate the bowel assessment preparation using the recorded colonoscopy videos from 50 consented normal risk patients. In the second phase, technological and machine user interface refinements will be identified and completed. Finally, the third phase will be a sham controlled prospective study of Colometer versus standard care in 100 consented average risk patients undergoing screening colonoscopy as performed by 10 consented endoscopists.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2013

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2013

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

September 26, 2013

Completed
29 days until next milestone

First Posted

Study publicly available on registry

October 25, 2013

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
Last Updated

August 19, 2016

Status Verified

January 1, 2016

Enrollment Period

2.3 years

First QC Date

September 26, 2013

Last Update Submit

August 17, 2016

Conditions

Keywords

colonoscopyquality assurance

Outcome Measures

Primary Outcomes (1)

  • %Clear

    This is defined as the Percentage of the total withdrawal time where the withdrawal velocity is below a set speed limit and the view is clear (ie, not blurry) as measured by the software. Visualization of the colon lumen is ideal with a slow, non-blurry view in order to detect polyps.

    Measurement will occur during the withdrawal phase as indicated by the physician during the colonoscopy procedure; on average, 12 minutes

Secondary Outcomes (2)

  • Average withdrawal velocity

    Measurement will occur during the withdrawal phase as indicated by the physician during the colonoscopy procedure; on average, 12 minutes.

  • Ottawa Stool Score

    Measurement will occur during the withdrawal phase as indicated by the physician during the colonoscopy procedure; on average, 12 minutes.

Study Arms (3)

Colometer

EXPERIMENTAL

Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.

Other: Colometer

Sham Software

SHAM COMPARATOR

An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.

Other: Sham Software

Control

NO INTERVENTION

Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.

Interventions

Real time software based image analysis tool.

Colometer

Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.

Sham Software

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients: patients categorized as normal risk who have been referred for screening colonoscopy at the Forzani \& MacPhail Colon Cancer Screening Centre in Calgary, Alberta
  • Endoscopists: Gastroenterologists with practices at the Forzani \& MacPhail Colon Cancer Screening Centre, Calgary, Alberta

You may not qualify if:

  • Patients: patients who are not categorized as normal risk

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Forzani&MacPhail Colon Cancer Screening Centre

Calgary, Alberta, T2N 4Z6, Canada

Location

MeSH Terms

Conditions

Colonic Neoplasms

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Study Officials

  • Christopher N Andrews, MD MSc

    University of Calgary

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

September 26, 2013

First Posted

October 25, 2013

Study Start

September 1, 2013

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

August 19, 2016

Record last verified: 2016-01

Locations